RxDoctor Payments Data

Patrick Danaher, DO

Pain Medicine · Missoula, MTNPI 1992794010

Payments from drug & device makers

What this record shows

Medtronic accounts for 72.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $2,766 and has fallen 89.9% since, to $281 in 2025.

$6,298in general payments, 2019–2025

Across 87 payments — averaging $72.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Boston Scientific$605
  • AbbVie$375
  • Amgen$141
  • Heron Therapeutics, Inc.$115
  • Piramal Critical Care$91
  • plus $378 from 11 others

What the payments were for

  • Travel & lodging$2,87446%
  • Food & beverage$3,42454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pain medicine providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$100,773
Medicare patients
264
Services billed
1,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Morphine Sulfate ErMorphine Sulfate30$4,475
Buprenorphine Hcl14$1,557
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen82$1,484
Fentanyl19$870
Tramadol Hcl86$804
Oxycodone Hcl50$786
Gabapentin56$565
Pregabalin69$526
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen26$491
Topiramate32$337
Methadone Hcl13$286
Duloxetine Hcl15$244
Acetaminophen-CodeineAcetaminophen With Codeine11$229
Methocarbamol21$181
Meloxicam27$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Upsher-smith Laboratories LLCTopiramate$18$33732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pain medicine providers in Montanaon file to place this against a meaningful peer group, so we don't.

Other pain medicine in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →